[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Declines More Than Market: Some Information for Investors",
    "summary": "AbbVie (ABBV) concluded the recent trading session at $219.99, signifying a -1.18% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=e1bc6c27a17276cda56b7cda6ab048f501b88f28285249058dfc0cdc936ddf59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758750304,
      "headline": "AbbVie (ABBV) Declines More Than Market: Some Information for Investors",
      "id": 136879403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) concluded the recent trading session at $219.99, signifying a -1.18% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=e1bc6c27a17276cda56b7cda6ab048f501b88f28285249058dfc0cdc936ddf59"
    }
  },
  {
    "ts": null,
    "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
    "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758735634,
      "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
      "id": 136865405,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162606801/image_1162606801.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Kings: September 2025",
    "summary": "Discover which Dividend Kings outperformed the SPY in 2024, top stock picks, growth outlooks, and find undervalued opportunities.",
    "url": "https://finnhub.io/api/news?id=3e6cbbdf3db3c5e8c25ad1d3ffcb9866ab9fe4541eb1d96cdb1b4444696daa1f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758728950,
      "headline": "Best Dividend Kings: September 2025",
      "id": 136864560,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156211986/image_2156211986.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover which Dividend Kings outperformed the SPY in 2024, top stock picks, growth outlooks, and find undervalued opportunities.",
      "url": "https://finnhub.io/api/news?id=3e6cbbdf3db3c5e8c25ad1d3ffcb9866ab9fe4541eb1d96cdb1b4444696daa1f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
    "summary": "Amgen: Imdelltra Could Be The Next Game Changer",
    "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758709050,
      "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
      "id": 136861111,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78"
    }
  }
]